Search

Your search keyword '"Obara, Wataru"' showing total 13 results
Start Over Author "Obara, Wataru" Journal japanese journal of clinical oncology
13 results on '"Obara, Wataru"'

1. Prevalence of germline BRCA1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice.

Author

Maekawa, Shigekatsu, Takata, Ryo, Sekiguchi, Kie, Kagabu, Masahiro, Toyoshima, Moe, Tamada, Shinji, Takahashi, Kenta, Ikarashi, Daiki, Matsuura, Tomohiko, Kato, Renpei, Kato, Yoichiro, Kanehira, Mitsugu, Sugimura, Jun, Abe, Takaya, Baba, Tsukasa, and Obara, Wataru

Published
2024
Full Text
View/download PDF

2. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study)

Author

Kojima, Takahiro, primary, Kato, Renpei, additional, Sazuka, Tomokazu, additional, Yamamoto, Hayato, additional, Fukuda, Shohei, additional, Yamana, Kazutoshi, additional, Nakaigawa, Noboru, additional, Sugino, Yusuke, additional, Hamamoto, Shuzo, additional, Ito, Hiroaki, additional, Murakami, Hiroshi, additional, and Obara, Wataru, additional

Published
2022
Full Text
View/download PDF

3. Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association

Author

Hara, Tomohiko, Fujimoto, Hiroyuki, Kondo, Tsunenori, Shinohara, Nobuo, Obara, Wataru, Kimura, Go, Kume, Haruki, Nonomura, Norio, Hongo, Fumiya, Sugiyama, Takayuki, Kanayama, Hiro-omi, Takahashi, Masayuki, Fukumori, Tomoharu, and Eto, Masatoshi

Published
2017
Full Text
View/download PDF

4. Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association

Author

Nakajima, Nobuyuki, primary, Miyajima, Akira, additional, Shinohara, Nobuo, additional, Obara, Wataru, additional, Kondo, Tsunenori, additional, Kimura, Go, additional, Kume, Haruki, additional, Fujimoto, Hiroyuki, additional, Sugiyama, Takayuki, additional, Nonomura, Norio, additional, Hongo, Fumiya, additional, Fukumori, Tomoharu, additional, Takahashi, Masayuki, additional, Kanayama, Hiro-omi, additional, and Eto, Masatoshi, additional

Published
2022
Full Text
View/download PDF

8. Corrigendum to: Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program

Author

Kume, Haruki, primary, Homma, Yukio, additional, Shinohara, Nobuo, additional, Obara, Wataru, additional, Kondo, Tsunenori, additional, Kimura, Go, additional, Fujimoto, Hiroyuki, additional, Nonomura, Norio, additional, Hongo, Fumiya, additional, Sugiyama, Takayuki, additional, Takahashi, Masayuki, additional, Kanayama, Hiro-omi, additional, Fukumori, Tomoharu, additional, and Eto, Masatoshi, additional

Published
2019
Full Text
View/download PDF

10. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up

Author

Tomita, Yoshihiko, primary, Kondo, Tsunenori, additional, Kimura, Go, additional, Inoue, Takamitsu, additional, Wakumoto, Yoshiaki, additional, Yao, Masahiro, additional, Sugiyama, Takayuki, additional, Oya, Mototsugu, additional, Fujii, Yasuhisa, additional, Obara, Wataru, additional, Motzer, Robert J, additional, and Uemura, Hirotsugu, additional

Published
2019
Full Text
View/download PDF

11. Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program

Author

Kume, Haruki, primary, Homma, Yukio, additional, Shinohara, Nobuo, additional, Obara, Wataru, additional, Kondo, Tsunenori, additional, Kimura, Go, additional, Fujimoto, Hiroyuki, additional, Nonomura, Norio, additional, Hongo, Fumiya, additional, Sugiyama, Takayuki, additional, Takahashi, Masayuki, additional, Kanayama, Hiro-omi, additional, Fukumori, Tomoharu, additional, and Eto, Masatoshi, additional

Published
2019
Full Text
View/download PDF

13. Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study.

Author

Hayakawa N, Kikuchi E, Kaneko G, Yamashita R, Ikarashi D, Endo Y, Usui K, Obara W, Oyama M, and Kondo Y

Abstract

Background: Enfortumab vedotin (EV) was approved for patients with metastatic urothelial carcinoma (mUC) who progressed after anticancer therapy on September 2021 in Japan. The association between the occurrence of EV-related side effects and clinical outcome remains to be elucidated., Methods: We identified 97 mUC patients treated with EV therapy at our five institutions from the date of approval to March 2023. The median follow-up period was 7.0 months. We retrospectively analyzed the efficacy and safety of EV., Results: The median age of the patients was 71 years old, 39% had PS of 1 or more, and 56.7% had primary tumor in upper urinary tract. Overall response rate (ORR) to EV therapy, median progression-free survival (PFS), and overall survival (OS) were 43.3%, 7.52 months, and 12.78 months, respectively. Any grade of treatment-related skin disorder, dysgeusia, peripheral neuropathy, gastrointestinal disorder, and hyperglycemia occurred in 61 (62.9%), 36 (37.1%), 34 (35.1%), 29 (29.9%), and 18 (18.6%) patients, respectively. The patients with EV-associated peripheral neuropathy had significantly higher ORR (58.8% vs. 34.9%, P = .032) and longer median PFS (8.05 vs. 6.31 months, P = .017) and OS (not reached vs. 11.57 months, P = .008, respectively) than those without. The occurrence of peripheral neuropathy after EV treatment and the presence of peritoneal dissemination were factors independently associated with PFS (hazard ratio = 0.46, P = .008 and hazard raito = 3.83, P = .004, respectively) and OS (hazard ratio = 0.30, P = .005 and hazard raito = 4.53, P = .002, respectively)., Conclusions: The occurrence of EV-related peripheral neuropathy might be associated with the efficacy of EV therapy in mUC patients., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results